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Background. A patent foramen ovale (PFO) is a rare cause of hypoxemia and clinical symptoms of dyspnea. Due to a right-to-left
shunt, desaturated blood enters the systemic circulation in a subset of patients resulting in dyspnea and a subsequent reduction in
quality of life (QoL). Percutaneous closure of PFO is the treatment of choice. Objectives. )is retrospective multicentre study
evaluates short- and long-term results of percutaneous closure of PFO in patients with dyspnea and/or reduced oxygen saturation.
Methods. Patients with respiratory symptoms were selected from databases containing all patients percutaneously closed between
January 2000 and September 2018. Improvement in dyspnea, oxygenation, and QoL was investigated using pre- and post-
procedural lung function parameters and two postprocedural questionnaires (SF-36 and PFSDQ-M). Results. )e average follow-
up period was 36 [12–43] months, ranging from 0months to 14 years. Percutaneous closure was successful in 15 of the 16 patients.
All patients reported subjective improvement in dyspnea immediately after device deployment, consistent with their im-
provement in oxygen saturation (from 90± 6% to 94 [92–97%] on room air and in upright position) (p< 0.05). Both ques-
tionnaires also indicated an improvement of dyspnea and QoL after closure. )e two early and two late deaths were unrelated to
the procedure. Conclusion. PFO-related dyspnea and/or hypoxemia can be treated successfully with a percutaneous intervention
with long-lasting benefits on oxygen saturation, dyspnea, and QoL.
1. Introduction
A foramen ovale is a flap-like opening between the right and
left atrium of the heart during fetal life. It normally closes
during infancy but remains patent (patent foramen ovale or
PFO) in approximately 25% of humans. A minority of subjects
with a PFO may develop clinical symptoms [1–4] such as a
paradoxical embolus and is suspected to be even related to
migraine and sleep apnea. More rarely, it may cause profound
hypoxia and symptoms of dyspnea. Symptoms can occur late
in life and may be precipitated by a cardiac or extracardiac
event, such as a pneumonectomy with a shift of the medias-
tinum, aortic root aneurysm or elongation, kyphosis, and
unilateral paralysis of the diaphragm [5]. )ese mechanical
distortions may change the position of the atrial septum rel-
ative to the inferior vena cava, thereby significantly increasing
the degree of shunting [6]. In symptomatic patients with PFO,
percutaneous closure is the treatment of choice [3, 5, 7].
)e aim of the current retrospective study was to
evaluate patients suffering from PFO-related dyspnea the
short- and long-term effects of percutaneous closure on
dyspnea, physiological outcome, and quality of life.
Hindawi
Journal of Interventional Cardiology
Volume 2020, Article ID 9813038, 8 pages
https://doi.org/10.1155/2020/9813038
2. Materials and Methods
2.1. Study Design and Patient Data. A multicentre study was
performed in three Belgian hospitals: Ghent University
Hospital (UZGent), University Hospital of Antwerp (UZA),
and ZNA Middelheim, Antwerp (ZNA). Listings from the
catheterization laboratories and the billing section of the
hospital’s pharmacist were used to identify potential cases.
)ese were subsequently cross-referenced to exclude dou-
bles and completed with cases that some cardiologists re-
membered. To be included in the study, the indication for
PFO closure had to be dyspnea and/or hypoxemia in all the
patients in order to include as many patients as possible.
Patients with other indications for closure, for example,
paradoxical embolus, decompression sickness in divers, or
migraine, were excluded. Patient characteristics, such as age,
gender, cardiovascular risk factors, and duration of com-
plaints, were obtained by consulting the local electronic
patient database or the paper patient files, classified and
stored in a database to assess the pre- and postoperative
clinical status.
2.2. Measurement of QoL. Data on QoL were obtained
prospectively by sending the patients the validated trans-
lations in Dutch of two questionnaires by email: the Medical
Outcomes Study 36-Item Short-FormHealth Survey (SF-36)
and the Pulmonary Functional Status and Dyspnea Ques-
tionnaire, Modified version (PFSDQ-M).
)e SF-36 is a set of generic, coherent, and easily ad-
ministered quality-of-life measures, consisting of eight do-
mains: physical functioning, role limitations due to physical
problems, bodily pain, general health, vitality, social func-
tioning, and role limitations due to emotional problems and
mental health. For each domain, the score ranges from 0
(worst) to 100 points (best). )e results can be compared
with the averages in the Medical Outcomes Study [8].
)e PFSDQ-M was developed to quantify the experi-
enced change in performing ADL compared with the period
before disease onset and symptoms of dyspnea and fatigue
related to ADL. )e questionnaire analyzes ten common
activities, for example, putting on a shirt and climbing the
stairs. Scores range from 0 (no dyspnea) to 10 points (severe
dyspnea). PFSDQ-M has been translated into eight lan-
guages and is used internationally to evaluate dyspnea [9].
)e design of the study was approved by the Ethics
Committee of UZGent, UZA, and ZNA on the following
dates, respectively: August 4, 2017; March 26, 2018; and May
9, 2018.
2.3. Data Processing and Confidentiality. Data collection of
the three hospitals was performed in the same way. First, the
informed consent was sent to the patients. After their ap-
proval, the retrospective data were retrieved from the
electronic patient database and the SF-36 and PFSDQ-M
questionnaires were sent. )ose who did not answer within
one month received a reminder by email or by phone.
All patients signed an informed consent to participate
and collected data were kept confidential. Refusing to
participate without any justification had no impact on future
care. Patients were informed that they could withdraw from
the study at any stage without victimization or denial of
treatment.
2.4. Statistical Analysis. IBM SPSS Statistics 24 (Statistical
Package for the Social Sciences; IBM Corporation, Armonk
NY) was used to process the parameters and questionnaires
mentioned above, assess their distribution, calculate the
averages, standard deviations, and quartiles, run the Wil-
coxon tests, and create the charts.
)e Shapiro–Wilk test, histograms, Q-Q plots, and
boxplots were used to assess normality. Normally distributed
data were expressed as mean (±SD) and nonnormally dis-
tributed data as mean and quartiles [Q1–Q3]. )e Wilcoxon
signed-rank test was used to analyze the difference between
pre- and postprocedural parameters.
Since no questionnaires before closure have been taken,
scores after PFO closure were compared with SF-36 scores of
a Dutch standard population (by Kruijshaar et al. [10]) and
with scores of a patient group with advanced COPD (by
Janssen et al. [11]).
3. Results
3.1. Selection of Patients. Between January 2000 and Sep-
tember 2018, 1.287 patients underwent percutaneous PFO
closure at UZGent, UZA, and ZNA.
Identification of patients in UZGent was based on two
lists: one from the catheterization lab (99 patients) and one
from the pharmacist (135 patients). Doubles were excluded,
109 medical files remained, and only those patients in
whom dyspnea and/or hypoxemia was the indication for
PFO closure were retained. )is ultimately led to the in-
clusion of six patients (Figure 1). Five of these returned
their questionnaires. )e mental disability (not related to
PFO closure) of the sixth patient prevented her to fill in the
questionnaires.
Cardiologists in charge of the catheterization laboratory
at UZA provided data required for the present study. Two
out of 387 patients underwent percutaneous PFO closure
because of severe dyspnea. One patient had undergone the
intervention before the digitalization of patient records. A
case report with few demographic and functional data was
the only source related to this patient and questionnaires
were not sent due to missing contact details. As the other
patient passed away, QOL was not obtained either.
)e dataset of ZNA contained 791 PFO closures since
January 1, 2000, from which eight patients were included in
this study, of whom three had already passed away. Of the
remaining five patients, only three filled in the question-
naires, whereas the treating physicians of the remaining two
patients claimed that they were still in very good physical
condition and did not exhibit any dyspnea. )e lack of
digitalization of patient records caused the data from the
three deceased patients to not be as extensive as most of the
digitalized files. For one of these, some data were retrieved
from a case report (personal communication) [12].
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Eventually, the database contained data of 16 patients, of
whom 12 were still alive and 8 filled in the two question-
naires.)e devices used to close the PFO are listed in Table 1.
3.2. Patients’ Baseline Characteristics and Follow-Up.
Baseline characteristics of the 16 patients, expressed either as
mean± SD or mean [quartile 1–quartile 3], are presented in
Table 2. Mean age [Q1–Q3] at time of closure was 59 [50–75]
years and 50% of patients were female. Mean (±SD) New
York Heart Association Functional Classification (NYHA)
was 3.0± 0.8.
)e most relevant associated medical conditions are
summarized in Table 3. Pneumonectomy was the most
common surgical procedure (n� 2). )e average duration
[Q1–Q3] of dyspnea before percutaneous intervention was 6
[1–8] months, ranging from a few days to 24 months.
)e average follow-up period was 36 [12–42] months,
with a range of 0–181 months and 6 patients being lost to
follow-up. Two early deaths were caused by acute respiratory
failure on top of a preexisting chronic respiratory failure of
pulmonary etiology and bronchial cancer. Among the two
late deaths, one was attributed to a carcinoid tumor and the
other one being of unknown origin.
3.3. Postprocedural PhysiologicalOutcomes. 14 of 15 patients
with successful closure reported complete resolution of their
Agreed participation
Analysis
Invitation
Enrollment
Selected (n = 6)
Analysed (n = 6)
Excluded from analysis (n = 0)(i)
Permitted to use their medical data (n = 6)
Did not fill in questionnaires (due to mentally handicapped) (n = 1)
Declined to participate (n = 0)
Do not speak Dutch (n = 0)
(i)
(ii)
(iii)
(iv)
Excluded (n = 228)
Not meeting inclusion criteria (n = 103)
Doubles (n = 125)
(i)
(ii)
Assessed for eligibility (n = 234)
Catheterization lab (n = 99) 
Pharmacist (n = 135)
(i)
(ii)
Firstly: received invitation to participate by post (n = 6)
Secondly: questionnaires sent a second time by post (n = 4)
Lastly: patients contacted by telephone (n = 1)
Did not received invitation (due to wrong contact information) (n = 0)
(i)
(ii)
(iii)
(iv)
Figure 1: Consort diagram UZGent.
Table 1: Used devices.
Occlutech Figulla® flex II occluder 6 (37.50)AMPLATZER™ septal occluder 3 (18.75)
Nit-occlud® 2 (12.50)Hyperion™ PFO occluder 1 (6.25)
STARFlex occluder 1 (6.25)
Values are n (%).
Table 2: Baseline characteristics.
Age, years 59 [50–75]
Male/female 8/8
Alive n� 10
Unknown n� 1
BMI, kg/m2 [10] 25.2± 3.70
NYHA functional class [7] 3.0± 0.8
NYHA functional class (I/II/III/IV) 0/2/3/2
Duration dyspnea, months [9] 6 [1–8]
Follow-up, months 36 [12–42]
Spontaneous shunt [12] n� 6
Cardiovascular risk factors
Hypertension [8] n� 3
Tobacco use, pack-years 10 [0–15]
Normally distributed values are mean± SD; nonnormally distributed values
are mean [Q1–Q3]. Numbers between brackets indicate number of patients
from whom data that were obtained. BMI� body mass index; NYHA�New
York Heart Association.
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dyspnea complaints after closure. One patient had an initial
improvement, but three months after closure she experi-
enced shortness of breath again, which was ultimately not
considered as a consequence of her PFO. Moreover, oxygen
saturation improved statistically significantly (p � 0.014)
immediately after device deployment (preprocedure:
90.2± 6%; postprocedure: 94.0% [92%–97%] on room air).
Percutaneous closure of a PFO had, however, no substantial
impact on the other outcomes such as PaO2, PaCO2 or
pulmonary function parameters, although a trend toward
statistical significance (p � 0.08) was seen for PaO2
(Table 4).
In one of the 16 patients a small residual clinically ir-
relevant left-to-right shunt across the occluder device could
be identified. )at patient was readmitted for a redo pro-
cedure, which was not successful because of technical issues.
Repeat interventions were not required in the remaining 15
patients and major complications were not recorded. One
patient experienced pain at the femoral access site and had a
transient reduction in hemoglobin shortly after the proce-
dure, which was uneventful. Long-term adverse events
suggesting device malfunction were not reported.
3.4. Quality of Life. Mean scores of the patients after PFO
closure for the different domains of the SF-36 are shown in
Figure 2. Mean score was 57.5/100 for physical functioning,
65.6/100 for role limitations due to physical health, and 59.3/
100 for general health. Overall, all scores after closure
exceeded the threshold of 50 points, which corresponds with
the general population norm according to Kruijshaar et al.,
thus indicating a favorable change in QoL [10]. Health status
after PFO closure was lower compared to the standard
population, but better than in the COPD population. )e
lower score in QoL compared to that of the standard
population could in part be attributed to 2 out of the 8
patients with severe osteoporosis and dyspnea due to a poor
physical condition. )ese comorbidities negatively affected
the averages, since the remaining 6 patients reported scores
that approximated the averages of the standard population.
QoL as assessed with SF-36 of patients after PFO closure
invariably exceeded that seen in COPD patients [11].
)e PFSDQ-M questionnaire, used to evaluate the change
in dyspnea when performing activities of daily life, increased
by 2.05± 2.56 points after closure, which corresponded to a
slight improvement. When asked about the current degree of
dyspnea and fatigue experienced duringmost days of the year,
the average scores for dyspnea and fatigue were 1.90± 1.97
and 2.71± 3.48, respectively, corresponding to a mild degree
of fatigue and dyspnea in daily life.
4. Discussion
)is study of the impact of percutaneous PFO closure in 15
of the 16 patients not only demonstrates that the inter-
vention leads to an immediate improvement in oxygen
saturation and reduction of dyspnea after device deployment
but is the first to evaluate the long-term effect of percuta-
neous PFO closure on QoL.
Over the last two decades, only five case series regarding
percutaneous PFO closure in patients with dyspnea have
been published (Table 5). Only two of these contained
substantially more patients than the present series
[5, 13–16]. )ese studies are not completely comparable to
the current one, as some series contain only patients with
platypnea-orthopnea syndrome (POS), while others in-
cluded only patients with hypoxemia [5, 13–16]. Our study
included all patients with PFO-related dyspnea and/or
hypoxemia. Moreover, the present study—in contrast with
the previous series—has a mean duration of follow-up of 36
months (range: 0 months–14 years) and ranged between 11
and 26 months in the previous ones. )is longer follow-up
period of up to 14 years not only allowed concluding the
long-term safety of PFO closure in a context of dyspnea and/
or hypoxemia, but also convincingly demonstrates that the
beneficial effects of PFO closure in terms of QoL do not wean
away after several years.
Table 3: Most relevant associated conditions.
Congenital malformations 7
Pectus excavatum 1
Pectus carinatum 1
Kyphoscoliosis 1
Diaphragmatic hernia 2
Pulmonary hypoplasia 1
Dextroversion 1
Pulmonary pathology 15
Obstructive diseases 6
COPD 1
Asthma 2
Air trapping and hyperinflation 1
Emphysema 1
Alpha-1 antitrypsin deficiency 1
Restrictive lung disease 9
Fibrothorax 1
Pneumonia 2
Pneumonectomy 2
Interstitial lung disease 1
Unspecified restrictive disease 1
Elevated right hemidiaphragm 2
Cardiovascular pathology 10
Pericarditis 1
Endocarditis lenta 1
Unfolded aorta 1
Dilated ascending aorta 1
DVT 1
CVA 1
Atrial fibrillation 1
Coronary artery bypass grafting 1
Acute myocardial infarct 1
Edema lower limbs 1
Oncologic pathology 4
Lung carcinoma 2
Benign tumor breast 1
Carcinoid carcinoma 1
Platypnea-orthodeoxia syndrome 2
Reflux esophagitis/Barrett’s esophagus 3
Epilepsy 2
Values are n. COPD� chronic obstructive pulmonary disease; DVT�deep
vein thrombosis; CVA� cerebrovascular accident.
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Surprisingly, patient-reported outcomes have never been
investigated in this population. Our findings support that
PFO closure is not only an effective treatment of respiratory
symptoms but also yields long-lasting beneficial effects.
More specifically, QoL assessed with the SF-36 indicated that
most patients after PFO closure experienced a QoL which
exceeds that of COPD patients and almost equaled that of a
standard population.
)e improvement in SaO2 seen in the current study was
smaller than what has been reported in previous studies
[5, 13–16]. In these studies, however, preprocedural mean
SaO2 was lower, and, hence, there was more room for
improvement. )e improvements in SaO2 observed in the
current study did not translate into significant changes in
PaO2. )is could be attributed to the small sample size or a
few confounding factors such as the scatter of the
Table 4: Pre- and postprocedural parameters.
Before PFO closure After PFO closure p value
SaO2 standing (%) 90.2± 6.3 94.0 [92.0–97.0] 0.014Unknown n� 3 n� 5
PaO2 (mmHg) 64.9± 14.4 77.8± 16.4 0.080Unknown n� 6 n� 6
PaCO2 (mmHg) 33.7 [28.5–38.2] 36.8± 6.3 0.686Unknown n� 6 n� 11
SaO2 standing after 6MWT (%) 82.8 [77.0–87.8] 92.7± 4.0 0.109Unknown n� 12 n� 13
FEV1 (% of predicted) 92.0± 40.9 95.6± 55.6 0.271Unknown n� 7 n� 9
FVC (% of predicted) 101.8 [75.8–127.2] 104.4± 44.6 0.237Unknown n� 7 n� 9
Tiffeneau-Pinelli index (FEV1/FVC) (%) 77.6± 21.9 81.7± 29.5 0.866Unknown n� 6 n� 9
PEF (% of predicted) 100.9± 30.7 97.7± 32.5 0.173Unknown n� 8 n� 10
DLCO (% of predicted) 67.0± 14.4 64.6± 23.1 0.893Unknown n� 8 n� 10
Normally distributed values are mean± SD; nonnormally distributed values are mean [Q1–Q3]. SaO2 � oxygen saturation; PaO2 � partial pressure of oxygen;
PaCO2 � partial pressure of carbon dioxide; 6MWT�six-minute walk test; FEV1� forced expiratory volume in 1 second; FVC� forced vital capacity;
PEF� peak expiratory flow; DLCO� diffusing capacity for carbon monoxide.
Physical functioning
Physical role functioning
Emotional role
functioning
Vitality
Mental health
Social role functioning
Bodily pain
General health
perceptions
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Figure 2: Statistical analysis of SF-36 questionnaire in 8 patients after PFO closure. A slight impairment in quality of life (QoL) is seen in
comparison to a standard population. Scores after PFO closure are superior to the scores from patients with advanced COPD.
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preprocedural PaO2 and the comorbidities mentioned in the
next paragraph. Nevertheless, a trend toward a statistical
significance (p � 0.08) was observed.
PFO can be the cause of dyspnea in patients having a
normal SaO2. In a part of the patients, the respiratory center
will react on hypoxemia, causing hyperventilation and
dyspnea. Dyspnea increases the tidal volume and thus
normalizes the arterial saturation. As the reaction of the
respiratory center on hypoxemia can differ, other patients
will not react on hypoxemia and not become dyspneic [17].
A large number of patients included in the present study
suffered from severe cardiopulmonary comorbidities, a
finding also reported in other studies. Interestingly, pneu-
monectomy, ascending aorta aneurysm (or dilation), and
right hemidiaphragm elevation were also reported in the
four other studies, but not in that of Ilkhanoff [5, 13–16].
However, in the latter study, almost all patients suffered
from chronic pulmonary disease and congestive heart
failure.
)e technique of percutaneous PFO closure has been
reported to be safe, and the present data confirm this finding
[5, 13–16]. Indeed, no major procedure-related complica-
tions were observed and the overall mortality was not related
to the intervention. It is reasonable to attribute our success
rate and safety data of the PFO closing technique to the large
experience of the catheterization laboratories of the three
institutions involved, as these have performed more than
1200 similar procedures over the last 18 years.
4.1. Limitations. Although the long duration of follow-up
definitely represents a strength, this study has several lim-
itations. Firstly, this is a cross-sectional, retrospective study.
Moreover, PFO-related dyspnea can be considered as an
“orphan disorder,” and it is very unlikely that a randomized
clinical trial will ever be conducted to prove the efficacy of
PFO closure in patients with respiratory symptoms. A
second limitation of our study is that some parameters were
lacking due to the incompleteness of several patient records
or death. As a consequence, only eight patients could fill in
the questionnaires. All questionnaires were sent to the pa-
tients at the same point of time, causing vast differences in
time interval between PFO closure and assessment of QoL.
Moreover, confounding factors, such as the comorbidities
described in Table 3, might have affected QoL measurement,
particularly since a PFO-specific questionnaire has not been
developed so far, and the results of the SF-36 and PFSDQ-M
questionnaires are sensitive to pick up reductions in QoL
due to a variety of symptoms caused by other diseases. For
example, the eventual score of the SF-36 questionnaire in a
patient with severe osteoporosis was definitely more affected
by that aforementioned disorder than by a PFO-related
dyspnea. Finally, missing parameters in the study pop-
ulation, a typical feature of retrospective studies, render the
interpretation of some of the physiological data somewhat
problematic. Since it is very unlikely that randomized
controlled studies will ever be conducted in patients un-
dergoing a PFO closure because of dyspnea and/or hyp-
oxemia, cardiologists in charge of such patient should be
invited to design a national or even international multicentre
cohort study in which relevant data on procedural outcome
in patients with a closed PFO would be collected
prospectively.
)e limited sample size did not allow for a statistical
comparison of the QoL between the patients with low
saturation and those with normal saturation before the
intervention. )e aim was to include all patients with PFO-
related dyspnea and low oxygen saturation. )e mentioned
comparison is beyond the scope of the current study.
5. Conclusion
In conclusion, patients with PFO and reduced oxygen sat-
uration at rest and during exercise benefit from percuta-
neous PFO closure. )e PFO closure not only resulted in
immediate increase in systemic arterial saturation and im-
mediate improvement of the patients’ dyspnea status. )e
procedure is safe and leads to a long-lasting improvement of
dyspnea and QoL during long time follow-up. Overall,
Table 5: Published series of PFO closure because of dyspnea or desaturation.
Author Year Number ofpatients
Mean age
(years)
Closure
rate
Absolute
increase in
SaO2
Major in-hospital
complications
Mean
follow-up
period
Follow-up results
Gue´rin [13] 2005 78 67 97% 10% 2 unrelated deaths 16m
7 late deaths
(unrelated to
procedure)
Shah [14] 2016 52 66 100% 14% 2 unrelated deaths, 1AF, 1 VF 26m 2 late AF
Mojadidi
[5] 2015 17 63 94% 16% - 11m 64.8% improvement
Current
study 2018 16 59 94% 4% None 36m
2 early and 2 late
deaths (unrelated)
Ilkhanoff
[15] 2005 10 63 100% 9% 1 TIA — —
Zavalloni
[16] 2013 6 63
100% after
redo 17% 1 unrelated death 3m
1 TIA, 3 repeat
interventions
—, missing; SaO2, oxygen saturation; AF, atrial fibrillation; VF, ventricular fibrillation; TIA, transient ischemic attack.
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percutaneous PFO closure can be recommended to patients
suffering from PFO-related dyspnea and/or hypoxemia at
rest or during exercise.
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